SMTI vs. INGN, COCH, ZJYL, AVNS, SGHT, VNDA, NBTX, INZY, HOWL, and AXGN
Should you be buying Sanara MedTech stock or one of its competitors? The main competitors of Sanara MedTech include Inogen (INGN), Envoy Medical (COCH), Jin Medical International (ZJYL), Avanos Medical (AVNS), Sight Sciences (SGHT), Vanda Pharmaceuticals (VNDA), Nanobiotix (NBTX), Inozyme Pharma (INZY), Werewolf Therapeutics (HOWL), and AxoGen (AXGN). These companies are all part of the "medical" sector.
Sanara MedTech (NASDAQ:SMTI) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking, risk, valuation and institutional ownership.
8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 89.9% of Inogen shares are held by institutional investors. 54.1% of Sanara MedTech shares are held by company insiders. Comparatively, 1.0% of Inogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Sanara MedTech has a net margin of -6.62% compared to Inogen's net margin of -32.46%. Sanara MedTech's return on equity of -11.12% beat Inogen's return on equity.
Sanara MedTech currently has a consensus target price of $44.00, indicating a potential upside of 33.90%. Inogen has a consensus target price of $7.00, indicating a potential downside of 15.05%. Given Sanara MedTech's stronger consensus rating and higher probable upside, analysts clearly believe Sanara MedTech is more favorable than Inogen.
Sanara MedTech has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500. Comparatively, Inogen has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.
Inogen received 369 more outperform votes than Sanara MedTech when rated by MarketBeat users. Likewise, 70.44% of users gave Inogen an outperform vote while only 53.13% of users gave Sanara MedTech an outperform vote.
Sanara MedTech has higher earnings, but lower revenue than Inogen. Sanara MedTech is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.
In the previous week, Inogen had 13 more articles in the media than Sanara MedTech. MarketBeat recorded 14 mentions for Inogen and 1 mentions for Sanara MedTech. Inogen's average media sentiment score of 0.51 beat Sanara MedTech's score of 0.00 indicating that Inogen is being referred to more favorably in the news media.
Summary
Sanara MedTech beats Inogen on 10 of the 17 factors compared between the two stocks.
Get Sanara MedTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SMTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sanara MedTech Competitors List
Related Companies and Tools
